Monte Rosa Therapeutics, Inc. (GLUE) Stock Analysis
Last updated Oct 26, 2026
Health Check
Last analyzed Oct 23, 2026
- Financial Health 70
- Profitability 25
- Business Quality 50
- Balance Sheet 65
- Cash Flow 25
Why this rating?
Health 52/100 — Acceptable
Entry timing is weak right now. Quality may be fine; the setup is not.
Company overview
Monte Rosa Therapeutics, Inc. (GLUE) is a Biotechnology company in the Healthcare sector. Compound Radar rates Monte Rosa Therapeutics, Inc. 52/100 (Acceptable) due to solid business quality.
Investment profile
- Quality Moderate
- Growth Soft
- Balance Sheet Unknown
Financial highlights
Valuation
- Forward P/E -5.87
- EV/Revenue 11.89
Profitability
- Revenue Growth -61.3%
- Gross Margin 0.0%
- Operating Margin -547.8%
- Net Margin 0.0%
- ROE -42.7%
Financial strength
- Cash $621.10M
- Debt $37.99M
- Net Cash $583.12M
- Free Cash Flow $-27.50M
- Current Ratio 10.58
Similar companies
Peers in Biotechnology, ranked by Financial Health.
Latest quoted price for the name. Helps anchor the setup in today’s market level.
Health Entry- Aurinia Pharmaceuticals Inc. Biotechnology AUPH$17.25 83 Health 83 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Incyte Corporation Biotechnology INCY$116.60 82 Health 82 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- Catalyst Pharmaceuticals Inc Biotechnology CPRX$31.49 81 Health 81 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
- ADMA Biologics, Inc. Biotechnology ADMA$11.06 80 Health 80 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Innoviva, Inc. Biotechnology INVA$20.94 80 Health 80 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Strong Entry Strong EntryTiming looks favorable across trend, momentum, valuation, support, and catalysts.
- Alnylam Pharmaceuticals, Inc. Biotechnology ALNY$226.79 78 Health 78 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Halozyme Therapeutics, Inc. Biotechnology HALO$128.50 77 Health 77 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Wait WaitEntry timing is weak right now. Quality may be fine; the setup is not.
- Vertex Pharmaceuticals Incorporated Biotechnology VRTX$521.03 76 Health 76 / 100
Strong business quality across profitability, growth, balance sheet, and cash flow.
Watch WatchWorth tracking, but timing is mixed — not a clear setup yet.
FAQ
How Compound Radar scores and tracks Monte Rosa Therapeutics, Inc. (GLUE).